华润医药控股增持博雅生物股份，公司前三季度业绩承压

DoNews2025-02-11

近日，博雅生物（300294.SZ）发布公告称，收到控股股东华润医药控股的告知函。华润医药控股于2024年11月8日至2025年2月7日期间，通过深圳证券交易所交易系统以集中竞价交易方式累计增持公司股份510.65万股，占公司总股本的1.0127%。尽管控股股东积极增持，但博雅生物2024年前三季度的业绩表现较为疲软。报告期内，公司实现营业收入12.45亿元，同比下降43.16%；归母净利润为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2510808551?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-11 17:16","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2510808551","market":"hk","top_or_hot":-1,"title":"华润医药控股增持博雅生物股份，公司前三季度业绩承压","media":"DoNews","content":"<div>\n<p>近日，博雅生物（300294.SZ）发布公告称，收到控股股东华润医药控股的告知函。华润医药控股于2024年11月8日至2025年2月7日期间，通过深圳证券交易所交易系统以集中竞价交易方式累计增持公司股份510.65万股，占公司总股本的1.0127%。尽管控股股东积极增持，但博雅生物2024年前三季度的业绩表现较为疲软。报告期内，公司实现营业收入12.45亿元，同比下降43.16%；归母净利润为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211172212961f03ac&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>华润医药控股增持博雅生物股份，公司前三季度业绩承压</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n华润医药控股增持博雅生物股份，公司前三季度业绩承压\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-11 17:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211172212961f03ac&s=b><strong>DoNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，博雅生物（300294.SZ）发布公告称，收到控股股东华润医药控股的告知函。华润医药控股于2024年11月8日至2025年2月7日期间，通过深圳证券交易所交易系统以集中竞价交易方式累计增持公司股份510.65万股，占公司总股本的1.0127%。尽管控股股东积极增持，但博雅生物2024年前三季度的业绩表现较为疲软。报告期内，公司实现营业收入12.45亿元，同比下降43.16%；归母净利润为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211172212961f03ac&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211172212961f03ac&s=b","article_id":"2510808551","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211172212961f03ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2510808551","pubTimestamp":1739265361,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，博雅生物发布公告称，收到控股股东华润医药控股的告知函。华润医药控股于2024年11月8日至2025年2月7日期间，通过深圳证券交易所交易系统以集中竞价交易方式累计增持公司股份510.65万股，占公司总股本的1.0127%。尽管控股股东积极增持，但博雅生物2024年前三季度的业绩表现较为疲软。此次增持体现了华润医药控股对博雅生物未来发展的信心，但公司短期内仍面临较大的业绩压力。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03320":"华润医药","BK1191":"制药","BK1570":"华润系"},"translate_title":"China Resources Pharmaceutical Holdings increased its holdings of Boya Bio shares, and the company's performance in the first three quarters was under pressure","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"近日，博雅生物（300294.SZ）发布公告称，收到控股股东华润医药控股的告知函。华润医药控股于2024年11月8日至2025年2月7日期间，通过深圳证券交易所交易系统以集中竞价交易方式累计增持公司股份510.65万股，占公司总股本的1.0127%。尽管控股股东积极增持，但博雅生物2024年前三季度的业绩表现较为疲软。报告期内，公司实现营业收入12.45亿元，同比下降43.16%；归母净利润为4.13亿元，同比下降11.07%；扣非净利润为3.36亿元，同比下降6.96%；经营活动产生的现金流量净额为2.62亿元，同比下降50.08%。此次增持体现了华润医药控股对博雅生物未来发展的信心，但公司短期内仍面临较大的业绩压力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2510808551","isCrawlerRequest":true}